ArticleDiscover oncology2023

Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.

Lin Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.